Invivyd (NASDAQ:IVVD) Insider Sells $14,316.12 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Robert Allen III sold 17,043 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total value of $14,316.12. Following the sale, the insider owned 178,765 shares in the company, valued at approximately $150,162.60. The trade was a 8.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Invivyd Stock Up 17.2%

Shares of NASDAQ:IVVD traded up $0.13 during trading on Tuesday, hitting $0.87. The stock had a trading volume of 7,732,095 shares, compared to its average volume of 3,061,089. Invivyd, Inc. has a 12-month low of $0.48 and a 12-month high of $3.07. The stock has a market capitalization of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. The stock has a 50-day simple moving average of $0.77 and a two-hundred day simple moving average of $1.23.

Invivyd (NASDAQ:IVVD) last released its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The firm had revenue of $14.29 million for the quarter, compared to analyst estimates of $14.40 million. As a group, sell-side analysts forecast that Invivyd, Inc. will post -0.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Jupiter Topco LLC purchased a new stake in Invivyd during the second quarter worth $30,048,000. Perceptive Advisors LLC acquired a new position in Invivyd during the fourth quarter worth $53,809,000. BVF Inc. IL purchased a new position in Invivyd during the fourth quarter valued at $48,227,000. RA Capital Management L.P. purchased a new position in Invivyd during the third quarter valued at $18,831,000. Finally, BlackRock Inc. acquired a new stake in shares of Invivyd in the second quarter valued at about $14,076,000. 70.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on IVVD shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. BTIG Research restated a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a report on Tuesday. Finally, Wall Street Zen lowered shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.00.

More Invivyd News

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.